Feed ALT
AL

Altimmune, Inc.

ALT · NASDAQ

$3.30 +0.92% (+$0.03)
1M +10.00%
Market Cap $641.8M
P/E Ratio -
Div. Yield -
ROE 31.41%
Piotroski F-Score Weak
2/9
Valuation
50 /100
Fair
P/S 20,702.10x
P/B 1.35x
P/E N/A
Growth
60 /100
Stable
Book val. growth 6.67%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak
Gross margin 48,306.50%
Net margin 296,000.00%
Op. margin 323,306.00%
Quality
0 /100
Poor
ROIC 19.47%
ROE 31.41%
ROA 17.40%
Debt
69 /100
Low
Debt/Equity 0.08x
Current ratio 26.78x
Int. coverage -26.22x
Stability
31 /100
Unstable
Beta 0.18x
Rev. volatility 428.50%
EPS volatility 8.66%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ALT
Online

Despre companie

Altimmune, Inc. (ALT) is a biotechnology company focused on the development of immunotherapies and therapeutic products. The company specializes in the development of vaccines and therapeutics aimed at boosting the immune system and combating various infectious diseases. Their research spans areas such as respiratory diseases, hepatitis B, and other health challenges. Altimmune strives to innovate in the field of immunotherapy and introduce new treatment possibilities. The company leverages modern technologies and scientific research to achieve its goals. Investors interested in the biotechnology sector and healthcare innovations might see potential in Altimmune, Inc. (ALT) shares for growth in this dynamic field.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Jerome Benedict Durso

Employees

57

Headquarters

Gaithersburg

Evenimente viitoare

05 NOV.

Earnings

Upcoming earnings report

51d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.